Shionogi & Co., Ltd. (TYO:4507)
Japan · Delayed Price · Currency is JPY | Market Cap | 2.37T +14.9% |
| Revenue (ttm) | 499.68B +14.0% |
| Net Income | 205.16B +20.4% |
| EPS | 241.04 +20.3% |
| Shares Out | 850.98M |
| PE Ratio | 11.57 |
| Forward PE | 11.18 |
| Dividend | 76.00 (2.71%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 3,453,700 |
| Open | 2,812.50 |
| Previous Close | 2,805.50 |
| Day's Range | 2,763.50 - 2,816.50 |
| 52-Week Range | 2,392.50 - 3,758.00 |
| Beta | 0.03 |
| Analysts | Buy |
| Price Target | 3,387.50 (+21.46%) |
| Earnings Date | Jul 30, 2026 |
About Shionogi &
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally. It is also involved in consumer healthcare business; manufacturing, sale, analytical testing, and pharmaceutical engineering of medicinal drugs and investigational drugs; contracted monitoring of epidemiological components in sewage; promotion of implementation in social infrastructure; and business related to providing data and information; develops and sells foothol... [Read more]
Full Company ProfileFinancial Performance
In fiscal year 2026, Shionogi &'s revenue was 499.68 billion, an increase of 14.01% compared to the previous year's 438.27 billion. Earnings were 205.16 billion, an increase of 20.37%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for 4507 stock is "Buy." The 12-month stock price target is ¥3,388, which is an increase of 21.46% from the latest price.
News
Shionogi & Slides: Investor presentation
Shionogi & has posted slides in relation to its latest quarterly earnings report, which was published on June 24, 2026.
Shionogi Announces FDA Approval of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure
OSAKA, Japan--(BUSINESS WIRE)--Shionogi Announces FDA Approval of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure.
US regulator approves oral drug from Japan's Shionogi to prevent COVID-19
Japan's Shionogi & Co said on Monday the U.S. Food and Drug Administration has approved its oral antiviral Ensitrelvir, commercially known as Xocova, for the preventive treatment of individuals wh...
New England Journal of Medicine Publishes Shionogi Study Demonstrating Ensitrelvir Prevents COVID-19 Following Exposure
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter “Shionogi”) announced that results from its global, double-bli...
Shionogi & Quarterly report: Q4 2026
Shionogi & has published its Q4 2026 quarterly earnings report on May 13, 2026.
Shionogi & Slides: Q4 2026
Shionogi & has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 13, 2026.
Shionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threats
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced that Shionogi Inc., a New Jersey-based s...
Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone)
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced that we have completed the transfer of a...
Shionogi Announces First Patients Enrolled in Global Phase 2 Clinical Trial in Adults with Late-Onset Pompe Disease
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced the first patients were enrolled in Espr...
Shionogi & Quarterly report: Q3 2026
Shionogi & has published its Q3 2026 quarterly earnings report on January 30, 2026.
Shionogi & Slides: Q3 2026
Shionogi & has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on January 30, 2026.
Japan's Shionogi boosts ViiV stake to 21.7% as Pfizer exits
Japan's Shionogi & Co said on Tuesday it would pay $2.13 billion for new shares in joint venture ViiV Healthcare, increasing its stake in the HIV drugmaker to 21.7% as U.S. drugmaker Pfizer exits its ...
Shionogi & Quarterly report: Q2 2026
Shionogi & has published its Q2 2026 quarterly earnings report on October 27, 2025.
Shionogi & Slides: Q2 2026
Shionogi & has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on October 27, 2025.
Shionogi & Quarterly report: Q1 2026
Shionogi & has published its Q1 2026 quarterly earnings report on July 28, 2025.
Shionogi & Slides: Q1 2026
Shionogi & has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on July 28, 2025.
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease
OSAKA, Japan & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) and Maze Therapeutic...